What is AltruBio?
AltruBio is a global biopharmaceutical company dedicated to the creation of targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. The organization is actively expanding its Research & Development teams, seeking innovative scientists to drive its mission forward. This strategic capital infusion is expected to accelerate the development of its novel therapeutic candidates.
How much funding has AltruBio raised?
AltruBio has raised a total of $288M across 2 funding rounds:
Series A
$63M
Series B
$225M
Series A (2021): $63M with participation from aMoon, CAM Capital, and BVF Partners
Series B (2024): $225M led by RA Capital Management, BVF Partners, and Soleus Capital
Key Investors in AltruBio
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in healthcare and life science companies. They aim to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
BVF Partners
BVF Partners L.P. is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments. Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies.
Soleus Capital
Soleus Capital is a healthcare investment firm that specializes in innovative life sciences sectors, including biotech, medtech, diagnostics, and genomics. The firm invests across the healthcare lifecycle, targeting both developmental-stage and commercial companies.
What's next for AltruBio?
The recent major strategic investment signifies a critical growth phase for AltruBio, likely enabling the company to scale its operations, expand its clinical trial programs, and further its research into cutting-edge antibody therapies. This backing positions AltruBio to make significant advancements in addressing unmet needs in oncology and immunology, potentially leading to new treatment paradigms.
See full AltruBio company page
